Skip to main content

Axis Bank Q2 Preview: NII may grow over 15% with 10% loan growth, asset quality key

HDFC Securities expects around 10 percent YoY loan growth and a marginal improvement in NIMs to drive core earnings (NII) growth of 16 percent YoY.

Private sector lender Axis Bank is expected to report a profit in the range of Rs 1,400-2,000 crore during Q2FY21 against a loss of Rs 112.1 crore in the year-ago quarter. The lender is also likely to report a sharp sequential growth in profit to lower provisions.

Net interest income (NII), the difference between the interest income from lending activities and the interest paid to depositor, is seen rising more than 15 percent year-on-year with 10 percent loan growth and 11 percent growth in deposits compared to the year-ago period, while pre-provision operating profit may grow in the 6-8 percent range YoY.



"We expect loan growth at 10 percent YoY with a greater focus on retail. We expect operating profit to grow at 8 percent YoY led by better cost controls," said Kotak Institutional Equities, which sees profit at Rs 1,982 crore and 17.5 percent growth in NII.

HDFC Securities sees around 10 percent YoY loan growth and a marginal improvement in NIMs are expected to drive core earnings (NII) growth of 16 percent YoY.

Asset quality is expected to be largely stable on a sequential basis with the focus on the quantum of loan restructuring but credit cost may stay higher.

"We expect slippages of around Rs 2,500 crore (around 2 percent of loans) subject to a court ruling. We expect gross NPL to remain flat QoQ. The focus would be on the expected quantum of restructured loans by Q4FY21 and update on the loan book as the moratorium is lifted," Kotak said.

KR Choksey expects the credit costs to remain elevated and the focus to remain on restructuring.

 

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Indigo Paints trades at over 55% premium in grey market after IPO price announcement

The grey market premium has increased significantly from Rs 400-500 on January 11 to Rs 840-850 on January 15. Indigo Paints, one of the fastest-growing paint companies in India, was trading at more than 50 percent premium over its higher issue price band of Rs 1,490 per share in the grey market after the announcement of IPO details. The premium in the grey market as of January 15 was at around Rs 840-850 per share, which means the grey market trading price stood at Rs 2,340-2,330 against the issue price of Rs 1,490, as per the data available on IPO Watch. The premium increased significantly from Rs 400-500 on January 11 to Rs 840-850 today. The grey market is an unofficial trading platform where shares get traded well before the allotment in an initial public offering and till the shares get listed on bourses. It generally estimates the expected listing price of a stock. "Currently Asian paints and Berger paints are trading at a PE of 111 and 148, respectively, while Indigo Paint...